Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
06/2003
06/11/2003CN1422849A 吲唑衍生物 Indazole derivative
06/11/2003CN1422622A Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine
06/10/2003US6576762 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors
06/10/2003US6576660 Methods and compositions for regulation of 5-α-reductase activity
06/10/2003US6576652 Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension.
06/10/2003US6576648 Compound with growth hormone releasing properties
06/10/2003US6576645 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
06/10/2003US6576644 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
06/10/2003US6576439 Contacting protein of given sequence with a test compound and detecting modulating activity; drug screening; can use for treatment of inflammatory conditions
06/10/2003US6576260 Sustained-release form of administration containing tramadol saccharinate
06/10/2003CA2265708C Lipoxin compounds and their use in treating cell proliferative disorders
06/06/2003CA2413479A1 Kit for reducing aching
06/05/2003WO2003046141A2 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
06/05/2003WO2003045999A2 Human vanilloid receptor protein and polynucleotide sequence encoding same
06/05/2003WO2003045984A2 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
06/05/2003WO2003045972A1 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17α-ALKYL-17β-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
06/05/2003WO2003045950A1 Pyrazolopyridine derivtives and their pharmaceutical use
06/05/2003WO2003045926A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003WO2003045920A1 4-aminoquinoline compounds
06/05/2003WO2003045902A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/05/2003WO2003045435A1 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
06/05/2003WO2003045412A1 Mint extract and related pharmaceutical compositions
06/05/2003WO2003045384A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/05/2003WO2003045380A1 Ilk inhibitors for the treatment of renal disease
06/05/2003WO2003045379A1 Hydrazonopyrazole derivatives and their use as therapeutics
06/05/2003WO2003045368A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045313A2 2-aminoquinoline compounds
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2002048124A3 Piperazine derivatives
06/05/2003WO2002031514A3 A method of determining the initial dose of vitamin d compounds
06/05/2003US20030105336 Pyrazole derivatives, their preparation and their use in pharmaceuticals
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105150 Method of treating of demyelinating diseases or conditions
06/05/2003US20030105148 Selective estrogen receptor modulators
06/05/2003US20030105147 Analgesics, sedatives, anesthetics
06/05/2003US20030105110 Novel compounds
06/05/2003US20030105107 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
06/05/2003US20030105106 5-HT receptor ligands and uses thereof
06/05/2003US20030105092 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105088 Thiol-based NAALADase inhibitors
06/05/2003US20030105085 Antagonists of MCP-1 function and methods of use thereof
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
06/05/2003US20030104570 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
06/05/2003US20030104500 Enzymatic assays for screening anti-cancer agents
06/05/2003US20030104478 Screening modulators of g-protein activity: for use in treatment of nervous system disorders
06/05/2003US20030104455 Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
06/05/2003US20030103974 Administering an antibodies or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss
06/05/2003US20030103969 Therapeutic treatment using an anti-CD14 antibody
06/05/2003CA2468292A1 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
06/05/2003CA2468280A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
06/05/2003CA2468184A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003CA2468159A1 4-aminoquinoline compounds
06/05/2003CA2468015A1 2-aminoquinoline compounds
06/05/2003CA2467831A1 Mint extract and related pharmaceutical compositions
06/05/2003CA2466870A1 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003CA2466867A1 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003CA2466845A1 Manipulation of cytokine levels using cd83 gene products
06/04/2003EP1316547A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)- n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient
06/04/2003EP1315965A2 Methods and compositions for in vitro targeting
06/04/2003EP1315840A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
06/04/2003EP1315835A2 Directed differentiation of embryonic cells
06/04/2003EP1315830A2 Compositions and methods for targeting peptides in humans in vivo
06/04/2003EP1315812A2 Modified polypeptides stabilized in a desired conformation and methods for producing same
06/04/2003EP1315804A2 Novel mmp-2 derivatives for use as inhibitors of integrin alpha vbeta 3
06/04/2003EP1315800A2 Human proteases
06/04/2003EP1315758A2 Methods and reagents for protease inhibition
06/04/2003EP1315735A1 Phosphate derivatives as immunoregulatory agents
06/04/2003EP1315727A2 7-oxo pyridopyrimidines
06/04/2003EP1315723A1 The hydrochloride salt of 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
06/04/2003EP1315718A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315717A1 Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315716A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315715A1 Quinazoline derivatives as kinase inhibitors
06/04/2003EP1315714A2 Quinazoline derivatives as alpha-1 adrenergic antagonists
06/04/2003EP1315705A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315704A1 2-guanidino-4-aryl-quinazoline
06/04/2003EP1315512A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
06/04/2003EP1315503A1 Treatment of urinary dysfunction
06/04/2003EP1315482A2 Water-dispersible encapsulated sterols
06/04/2003EP1252150B1 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
06/04/2003EP1140945B1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
06/04/2003EP0980244B1 Use of quinazoline compounds for the treatment of polycystic kidney disease
06/04/2003EP0968208B1 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
06/04/2003EP0944616B1 Bicyclic aryl carboxamides and their therapeutic use
06/04/2003EP0909175B1 Non-aqueous protic peptide formulations
06/04/2003EP0863875B1 New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
06/04/2003EP0775118B1 Benzimidazole derivatives having dopaminergic activity
06/04/2003CN1422273A 1,5-disubstituted-3,4-dihydro-1H-pyrimido [4,5-D] pyrimidi-2-one compounds and their use in treating CSBP/P38 kinase mediated diseases
06/04/2003CN1422271A Pyrrolopyrimidinone derivatives, process of preparation and use
06/04/2003CN1422270A Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines
06/04/2003CN1422263A Estrogen agonist/antagonist metabolites
06/04/2003CN1422262A 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
06/04/2003CN1422260A 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
06/04/2003CN1422157A Divided dose therapies with vascular damaging activity
06/04/2003CN1422152A Combination of organic compound
06/04/2003CN1422150A Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
1 ... 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 ... 562